340 related articles for article (PubMed ID: 31937612)
1. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.
Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q; Yin J; Shen J
Clin Cancer Res; 2020 Jun; 26(11):2681-2692. PubMed ID: 31937612
[TBL] [Abstract][Full Text] [Related]
2. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
[TBL] [Abstract][Full Text] [Related]
3. High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma.
Eliades P; Abraham BJ; Ji Z; Miller DM; Christensen CL; Kwiatkowski N; Kumar R; Njauw CN; Taylor M; Miao B; Zhang T; Wong KK; Gray NS; Young RA; Tsao H
J Invest Dermatol; 2018 Jul; 138(7):1582-1590. PubMed ID: 29408204
[TBL] [Abstract][Full Text] [Related]
4. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
[TBL] [Abstract][Full Text] [Related]
5. Identification of key genes in osteosarcoma - before and after CDK7 treatment.
An Y; Wang Y; Xu G; Liao Y; Huang G; Jin X; Xie C; Li Q; Yin D
Medicine (Baltimore); 2021 Oct; 100(39):e27304. PubMed ID: 34596127
[TBL] [Abstract][Full Text] [Related]
6. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
7. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Jiang YY; Lin DC; Mayakonda A; Hazawa M; Ding LW; Chien WW; Xu L; Chen Y; Xiao JF; Senapedis W; Baloglu E; Kanojia D; Shang L; Xu X; Yang H; Tyner JW; Wang MR; Koeffler HP
Gut; 2017 Aug; 66(8):1358-1368. PubMed ID: 27196599
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
[TBL] [Abstract][Full Text] [Related]
10. Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.
Wong RWJ; Ngoc PCT; Leong WZ; Yam AWY; Zhang T; Asamitsu K; Iida S; Okamoto T; Ueda R; Gray NS; Ishida T; Sanda T
Blood; 2017 Nov; 130(21):2326-2338. PubMed ID: 28978570
[TBL] [Abstract][Full Text] [Related]
11. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
Shi CS; Kuo KL; Chen MS; Chow PM; Liu SH; Chang YW; Lin WC; Liao SM; Hsu CH; Hsu FS; Chang HC; Huang KH
Cells; 2019 Nov; 8(11):. PubMed ID: 31752390
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
Zhong L; Yang S; Jia Y; Lei K
J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
Sun B; Mason S; Wilson RC; Hazard SE; Wang Y; Fang R; Wang Q; Yeh ES; Yang M; Roberts TM; Zhao JJ; Wang Q
Oncogene; 2020 Jan; 39(1):50-63. PubMed ID: 31462705
[TBL] [Abstract][Full Text] [Related]
15. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
[TBL] [Abstract][Full Text] [Related]
16. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
[TBL] [Abstract][Full Text] [Related]
17. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
[TBL] [Abstract][Full Text] [Related]
18. Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Pelish HE; Liau BB; Nitulescu II; Tangpeerachaikul A; Poss ZC; Da Silva DH; Caruso BT; Arefolov A; Fadeyi O; Christie AL; Du K; Banka D; Schneider EV; Jestel A; Zou G; Si C; Ebmeier CC; Bronson RT; Krivtsov AV; Myers AG; Kohl NE; Kung AL; Armstrong SA; Lemieux ME; Taatjes DJ; Shair MD
Nature; 2015 Oct; 526(7572):273-276. PubMed ID: 26416749
[TBL] [Abstract][Full Text] [Related]
19. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
